Brendan Manning, Ph.D.
Brendan Manning, Ph.D.
Professor and Acting Chair, Department of Molecular Metabolism (Harvard T.H. Chan School of Public Health
Affiliate Member of Cell Biology (HMS)

Brendan Manning, Ph.D. is a Professor and Acting Chair in the Department of Molecular Metabolism at the Harvard T.H. Chan School of Public Health. He received his PhD from Yale University in 2000 and was a postdoctoral fellow at Harvard Medical School. In 2004, Dr. Manning became the first faculty member hired in the then newly established Department of Genetics and Complex Diseases (later changed to Molecular Metabolism) at Harvard-Chan. Dr. Manning was an inaugural recipient of the National Cancer Institute’s Outstanding Investigator Award. 

Research in the Manning lab is defining the molecular interface between cellular signaling networks and metabolic networks, as it relates to both normal physiology and diseases with metabolic dysregulation as a key feature, including cancer, diabetes, and aging-related diseases. Research efforts are focused in part on defining the regulatory mechanisms and functions of a signaling network converging on the tuberous sclerosis complex (TSC) protein complex and the mammalian target of rapamycin (mTOR), which relay an array of extracellular and intracellular growth signals to control the balance between anabolic and catabolic metabolism in cells, tissues, and tumors.

665 Huntington Ave


Boston, MA 02115

The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth.
Authors: Authors: Schrötter S, Yuskaitis CJ, MacArthur MR, Mitchell SJ, Hosios AM, Osipovich M, Torrence ME, Mitchell JR, Hoxhaj G, Sahin M, Manning BD.
Cell Rep
View full abstract on Pubmed
Purine nucleotide depletion prompts cell migration by stimulating the serine synthesis pathway.
Authors: Authors: Soflaee MH, Kesavan R, Sahu U, Tasdogan A, Villa E, Djabari Z, Cai F, Tran DH, Vu HS, Ali ES, Rion H, O'Hara BP, Kelekar S, Hallett JH, Martin M, Mathews TP, Gao P, Asara JM, Manning BD, Ben-Sahra I, Hoxhaj G.
Nat Commun
View full abstract on Pubmed
Hepatic mTORC1 signaling activates ATF4 as part of its metabolic response to feeding and insulin.
Authors: Authors: Byles V, Cormerais Y, Kalafut K, Barrera V, Hughes Hallett JE, Sui SH, Asara JM, Adams CM, Hoxhaj G, Ben-Sahra I, Manning BD.
Mol Metab
View full abstract on Pubmed
Cancer Signaling Drives Cancer Metabolism: AKT and the Warburg Effect.
Authors: Authors: Hosios AM, Manning BD.
Cancer Res
View full abstract on Pubmed
James R. Mitchell (1971-2020).
Authors: Authors: Ristow M, Lee CH, De Bock K, Gladyshev VN, Hotamisligil GS, Manning BD.
Cell Metab
View full abstract on Pubmed
The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals.
Authors: Authors: Torrence ME, MacArthur MR, Hosios AM, Valvezan AJ, Asara JM, Mitchell JR, Manning BD.
View full abstract on Pubmed
IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex.
Authors: Authors: Valvezan AJ, McNamara MC, Miller SK, Torrence ME, Asara JM, Henske EP, Manning BD.
JCI Insight
View full abstract on Pubmed
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism.
Authors: Authors: Hoxhaj G, Manning BD.
Nat Rev Cancer
View full abstract on Pubmed
Fibroblastic reticular cells enhance T cell metabolism and survival via epigenetic remodeling.
Authors: Authors: Brown FD, Sen DR, LaFleur MW, Godec J, Lukacs-Kornek V, Schildberg FA, Kim HJ, Yates KB, Ricoult SJH, Bi K, Trombley JD, Kapoor VN, Stanley IA, Cremasco V, Danial NN, Manning BD, Sharpe AH, Haining WN, Turley SJ.
Nat Immunol
View full abstract on Pubmed
Author Correction: Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis.
Authors: Authors: Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, Liu D, Wan L, Zhai B, Yu Y, Yuan M, Kim BM, Shaik S, Menon S, Gygi SP, Lee TH, Asara JM, Manning BD, Blenis J, Su B, Wei W.
Nat Cell Biol
View full abstract on Pubmed